Trial Profile

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone; Hyaluronidase; Lenalidomide
Indications Multiple myeloma; Plasmacytoma
Focus Registrational; Therapeutic Use
Acronyms POLLUX
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

11 Mar 2025 Status changed from active, no longer recruiting to completed.
05 Nov 2024 Planned End Date changed from 14 Nov 2024 to 29 Nov 2024.
25 Sep 2024 Planned End Date changed from 30 Aug 2024 to 14 Nov 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com